Exela PharmSci, Inc. develops noninfringing pharmaceutical formulations that will be marketed as branded or generic alternatives to established name-brand products. Exela has multiple products in advanced stages of filing and/or commercialization with partners. Exela’s product portfolio spans several therapeutic categories and dosage forms, such as oral, injectable, and ophthalmic. In addition to its R&D center in Hyderabad, India, Exela owns a 20,000 sqft cGMP sterile manufacturing facility in Lenoir, North Carolina. The Lenoir facility can handle cytotoxic, high-potency compounds, and manufacture clinical Phase I-III as well as commercial scale products that are terminally sterilized or asceptically processed.